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Abstract 
To evaluate SNPs (single nucleotide polymorphism) in PROC (protein C gene) associated with pulmonary embolism 
(PE) susceptibility in North Chinese Han population. A case-control study design was used, and patients with PE and 
healthy participants were enrolled from the Emerging Department of the several hospitals in Weifang, Shandong, 
China. SNPs in PROC were genotyped using Mass ARRAY system. The allele frequency of rs199469469 was signifi-
cantly different between PE patients and the control [OR (95 % CI) = 5.00 (1.66–15.12), P = 0.004], and the difference 
remained significantly after controlling for age and gender [OR (95 % CI) = 5.34 (1.47–19.39), P = 0.011). The G(del)
G in the haplotype includes rs1799809|rs199469469|rs2069928 was of a significantly difference (P = 0.016) among PE 
patients and the controls, and remained significant (P = 0.015) after adjustment for age and sex. Our study reports 
that PROC SNPs (rs199469469) might be associated with PE susceptibility, with the G allele of rs199469469 serving as 
the protective factors for incidence of PE. These findings may contribute to the understanding and primary preven-
tion of PE.
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Background
The major thrombotic medical disorders include venous 
thromboembolism (VTE), a multifactorial disorder con-
sisting of deep venous thrombosis (DVT) and pulmonary 
embolism (PE). PE is one manifestation of venous throm-
boembolism (VTE) and is a frequent, recurrent and 
potentially fatal disease (Goldhaber and Bounameaux 
2012; Goldhaber 2012). PE contributes to 5–10  % of 
deaths in hospitalized patients and VTE is a leading 
preventable cause of in-hospitalized death (Alikhan 
et al. 2004; Cohen et al. 2008). In USA, the incidence of 
all DVT/PE events is 300,000–600,000 cases per year 
(approximately 1–2 per 1000 persons per year) and the 
mortality rates of all DVT/PE events is 60,000–100,000 
cases per year (Beckman et  al. 2010). However, it is 
difficult to estimate accurate mortality rates of the PE, 
because of the presence of related diseases and the large 
proportion of undiagnosed PE (Laack and Goyal 2004).
With the improvement of its diagnosis and the develop-
ment of access to healthcare, VT in Asian populations is 
now thought to be rising (Roberts et al. 2009; Zakai and 
McClure 2011).
PE is caused by both genetic and environmental fac-
tors, among which genetic factors account for up to 60 % 
of risk (Souto et  al. 2000). Studies have shown that sin-
gle nucleotide polymorphisms (SNPs) in genes (protein 
C gene, protein S gene and antithrombin gene) may con-
tribute to the susceptibility to PE (Roberts et  al. 2009; 
Suehisa et al. 2001). Protein C (PROC, or PC) is a vitamin 
K-dependent serine protease zymogen, which is an inac-
tive zymogen and can be stimulated by the thrombin–
thrombomodulin (TM)—endothelial protein C receptor 
complex on endothelial cell surfaces. TM-bound throm-
bin cleaves the 158–169 activation peptide of PC and 
generates activated PC (APC) (Wildhagen et  al 2011). 
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APC is a key component of the anticoagulation system. 
APC inhibits the coagulation pathway by proteolysis of 
coagulation factor Va (the activated form of coagulation 
factor V) and coagulation factor VIIIa (Cramer and Gale 
2011). The decreasing of APC level is an independent risk 
factor for both venous and arterial thrombosis (Soare and 
Popa 2010).
The human PROC is located on 2q13–q14 and com-
prises 9 exons. Up to date more than 200 mutations 
were identified in the PROC gene (D’Ursi et  al 2007). 
Most studies were conducted in Western populations, 
and few in the Asian population (Gandrille et  al. 1995; 
Miyata et al. 1998; Reitsma et al. 1991; Shen et al. 1997). 
These studies show that the mutation pattern of PROC 
is of significant ethnic differences, thus, some muta-
tions (Arg230Cys, Arg178Trp, Gln132X, Val297Met and 
Pro168Leu) are common in the Caucasian population, 
while the others (Phe139Val/ rs199469470, Arg169Trp/ 
rs759316085, Val297Met, Met364Ile, and G8857del) are 
observed in the Japanese population. So far, few stud-
ies have been published to investigate the association 
between PROC variants with incidence of PE in mainland 
China.
In this study, we investigated the association between 
PROC variants and incidence of PE in a case-control 
study of North China Han population.
Results
In total, 101 cases of PE (61 males and 40 females; with 
median age 63 year-old, ranged 24–85), and 279 healthy 
controls (187 males and 92 females; with median age 
65 year-old, ranged 48–87 year-old) were finally included 
in the study. Six polymorphisms in the PROC gene were 
genotyped through Mass ARRAY system, with success 
rate of 99.7, 96.8, 96.6, 92.1, 97.6 and 97.6% for rs1799809, 
rs199469469, rs2069928, rs7580688, rs2240817 and 
rs3771293, respectively (Fig. 1).
All the six polymorphisms in cases and controls 
were both confirmed to Hardy–Weinberg equilib-
rium (Table  1). Table  1 showed that the “del” allele of 
rs199469469 (AAG/del) was of allele difference between 
the case and the control (OR = 5.00, 95 % CI 1.66–15.12, 
P = 0.004), and the association remained significant after 
adjustment for age and sex (OR =  5.34, 95  % CI 1.47–
19.39, P  =  0.011). For the other 5 SNPs, no statistical 
significances were observed (Table  1). rs199469469 was 
associated with PE in genotype and dominant model, but 
not in recessive model (Table 2).
The frequencies of Haplotype were evaluated using 
the Chi-square test, and Logistic regression analysis 
was performed to adjust for age and gender. The results 
showed that Haplotype G(del)G frequency (rs1799809|r
s199469469|rs2069928) between the case and the control 
(P =  0.016) was of significant difference, and remained 
significant (P =  0.015) after adjustment for age and sex 
(Table 3).
We also described the allele frequency data in the pre-
sent study as well as 1000 genome project. Except for 
rs199469469, the allele frequency of other 5 SNPs are 
comparable among the present study and these in 1000 
Genome of different ethnic groups (Table 4). This paper 
confirms data reported by Tang et al. (2012b) who identi-
fied that the rs199469469 in PROC was associated with 
both decreased protein C anticoagulation activity and an 
increased risk of thrombosis in Chinese subjects of South 
China, whereas no allele frequency of rs199469469 were 
reported in 1000 Genome or other populations. There-
fore, the “del” allele of rs199469469 could be considered 
typical of Chinese people, and should be validated in 
large cohort of different ethnic groups.
Discussion
In this study, we investigated the association between 
PROC variants and the development of PE, and revealed 
that the rs199469469 (also designated as c.574_576del or 
p.Lys150del, located in exon 7 of the PROC gene) predis-
pose people to PE. The case-control study showed that 
variant confers an approximately 5.00-fold increased risk 
of PE in the north Chinese population, and the results 
persist after adjustment for age and sex (OR  =  5.34, 
P = 0.011).
PROC, with a single chain and synthesized by hepato-
cytes, is composed of a short activation peptide, a ser-
ine protease domain, carboxy-glutamic acid residue 
(Gla) domain, two epidermal growth factor (EGF)-like 
domains (Fisher et al. 1994; Perera et al. 2000). The dele-
tion of lysine in PROC (rs19469469) can caused confor-
mational changes in the protease domain (Chen et  al. 
2008), resulting in the elimination of a positive charge 
(Wildhagen et al. 2011). The most important is that the 
deletion is located at the ‘linking peptide (residues 137–
157)’, which precedes the activation peptide and excised 
upon protein C activation. Residues Gly142–Leu155 are 
well conserved among species, and previously researches 
showed the region is important for anticoagulant activ-
ity (Mesters et  al. 1993; Lu et  al. 2013). Factor-V-Lei-
den mutation in the coding sequence of F5 (Dahlbäck 
et  al. 1993; Koster et  al. 1993; Bertina et  al. 1994), pro-
thrombin-G20210A mutation in the 3′ UTR of F2 and 
antithrombin-Cambridge-II mutation in SERPINC1 are 
common genetic risk factors for VT in whites (Poort 
et al. 1996; Corral et al. 2007). However, these polymor-
phisms are rare in Asians, including Chinese populations. 
Little is known about the genetic background of VT, 
and no common genetic risk factors have been identi-
fied in the Chinese population until recently. Tang et  al 
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(2012a) carried out the first study on the genetic back-
ground of PC deficiency in the Chinese population, and 
identified a common mutation in PROC (rs146922325, 
c.565C>T) in a family study (first-degree relatives bear-
ing this variant had an 8.8-fold increased risk of venous 
thrombosis), which has been further verified by our case-
control study (the mutant allele conferred a high pre-
disposition to venous thrombosis (adjusted OR  =  7.34, 
95  % CI 3.61–14.94). Tang et  al (2012b, 2013) further 
identified that rs199469469 in PROC was associated with 
both decreased protein C anticoagulant activity and an 
increased risk of VTE in Chinese (Hubei Province), with 
an odds ratio of 2.93, and 2.84 (Tang et al. 2012b, 2013). 
The studies by Tang et al (2012a, b, 2013) were performed 
in Southern China, and our study performed in Northern 
China confirmed that rs199469469 in PROC was associ-
ated with an increased risk of VTE in Chinese.
Conclusion
We firstly showed that the “del” allele of rs199469469 
in PROC is associated with the increased risk of PE in a 
Northern Chinese Han population and the finding was 
consistent with that in Southern Chinese. Further epi-
demiologic studies are required to determine this asso-
ciation in larger populations, and functional studies are 
needed to determine the effect of this mutation contrib-
uting to susceptibility to PE. These studies will be a ben-
efit to early predication or primary prevention of PE.
Fig. 1 Genotyping of six SNPs in PROC gene
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Methods
Participants
This study was approved by the ethics committee of Wei-
fang People’s Hospital. A total of 101 unrelated patients 
diagnosed with PE in 2011 and 2012 were recruited from 
the Emerging Department of the hospitals in North 
China. The diagnosis of PE met the criteria recom-
mended by the European Society of Cardiology (ESC) 
published in 2008 (Torbicki et al. 2008), and the patients 
with PE for patent foramen ovale were not screened. The 
inclusion criteria were: (1) Chinese Han population; (2) 
> or  =  18  year-old. While the exclusion criteria were: 
(1) patients with acute liver disease or nephrotic syn-
drome; (2) recurrent venous thrombosis or pulmonary 
embolism; (3) patients with personal or family history 
of venous thromboembolism or other blood disease; (4) 
patients with the special history of drug use; (5) patients 
with chronic diseases such as hypertension; (6) patients 
with insertion of pacemaker.
Table 1 The allele frequency of SNPs in PROC in patients with PE and the controls
SNPs single nucleotide polymorphisms, CI confidence interval, OR odds ratio
a Adjusted for sex and age
SNPs Allele Hardy–Weinberg equilibrium Minor allele 
frequency (%)
Univariate analysis Multivariate analysisa
The cases The controls Case Control OR (95% CI) P OR (95% CI) P
GENO P GENO P
rs1799809 A>G 5/25/71 0.170 9/61/198 0.140 0.173 0.147 1.212 (0.784–1.874) 0.424 1.131 (0.714–1.791) 0.599
rs199469469 AAG>del 0/9/91 1.000 0/5/263 1.000 0.045 0.009 5.004 (1.656–15.120) 0.004 5.339 (1.470–19.390) 0.011
rs2069928 G>T 11/45/45 1.000 28/117/121 1.000 0.332 0.325 1.030 (0.730–1.453) 0.861 1.102 (0.759–1.601) 0.609
rs7580688 A>G 16/54/29 0.310 38/119/94 1.000 0.434 0.388 1.209 (0.866–1.687) 0.267 1.270 (0.867–1.859) 0.219
rs2240817 A>G 4/28/69 0.510 6/83/171 0.400 0.178 0.183 0.970 (0.635–1.482) 0.915 1.187 (0.742–1.899) 0.476
rs3771293 A>G 4/37/60 0.770 10/79/171 0.840 0.223 0.190 1.219 (0.819–1.813) 0.351 1.155 (0.739–1.805) 0.528
Table 2 the association between  SNP rs199469469 
with PE in three genetic models
Model Case Control P
GENO 0/9/91 0/5/263 0.003
DOM 9/91 5/263 0.003
REC 0/100 0/268 1.000
Table 3 The haplotype distribution of PROC (rs1799809|rs
199469469|rs2069928) in the cases and the controls
Padj adjust for age and gender
Haplotype F-Affected F-Control Chi-square P Padj
G(AAG)T 0.027 0.030 0.049 0.824 0.922
A(AAG)T 0.310 0.296 0.130 0.718 0.630
G(Del)G 0.030 0.007 5.790 0.016 0.015
G(AAG)G 0.119 0.111 0.107 0.743 0.958
A(AAG)G 0.514 0.556 1.037 0.309 0.209
Table 4 The minor allele frequency of selected SNPs in the present study and 1000 genome
CHB Han Chinese Beijing; CHS Southern Han Chinese; JPT Japanese in Tokyo; YRI Yoruba in Ibadan, Nigeria; CEU Utah residences with Northern and Western Ancestry
SNPs Minor allele The present study 1000 genome
Case Control CHB CHS JPT CEU YRI
rs1799809 G 0.173 0.147 0.175 0.152 0.139 0.409 0.806
rs199469469 del 0.045 0.009 – – – – –
rs2069928 T 0.332 0.325 0.374 0.295 0.255 0.248 0.088
rs7580688 G 0.434 0.388 0.369 0.371 0.260 0.313 0.588
rs2240817 G 0.178 0.183 0.151 0.133 0.130 0.152 0.120
rs3771293 G 0.223 0.190 0.199 0.219 0.130 0.152 0.278
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The controls were 279 ethnic matched healthy indi-
viduals recruited in physical examination. All the patients 
and the control have given their written consents to par-
ticipate in the study.
Selection of SNPs and genotyping
For the selection of candidate SNPs, we firstly down-
loaded all SNPs information in PROC region (including 
5000 bp in the upstream and 5000 bp in the downstream) 
from Hapmap (Version 3, Release 2, Analysis Panel 
CHB), then we screened the SNPs with Minor Allele Fre-
quency ≥0.10, and P  ≥  0.10 in Hardy–Weinberg Equi-
librium test, finally we selected the tag SNPs (r2 ≥ 0.80) 
using Tagger function of Haploview (Barrett et  al. 
2005). Five SNPs near PROC (rs1799809, rs199469469, 
rs2069928, rs7580688, rs2240817) meet the criteria. 
rs199469469 was also added because it was associated 
with both decreased protein C anticoagulation activity 
and an increased risk of thrombosis in Chinese subjects 
of South China (Tang et al. 2012b).
Genomic DNA was extracted from whole-blood sam-
ples using QIAamp DNA Blood Mini Kit (Qiagen, Ger-
man) according to the manual instructions. Genomic 
DNA samples were subsequently diluted to 25  ng/
μl. SNPs were genotyped using Mass ARRAY system 
(Sequenom, Inc., SanDiego, CA). Sequenom Mass-
ARRAY® Assay Design 3.0 software (Sequenom, Inc., 
San Diego, CA, USA) was used to design Multiplexed 
SNP Mass-EXTEND assays (Gabriel et  al. 2009). SNP 
genotyping was performed using the standard protocol 
recommended by the manufacturer with a Sequenom 
Mass-ARRAY® RS1000 (Sequenom, Inc.). Sequenom 
Typer 4.0 software was used for data management and 
analyses (Thomas et al. 2007).
Statistical analysis
The Hardy–Weinberg equilibrium (HWE) of each SNP 
was evaluated using the Chi-square test. Differences 
between groups were analyzed by a Student’s t test or 
Mann–Whitney U test depending on the distribution of 
the laboratory data for continuous variables. The asso-
ciations between PE and specific PROC genotypes were 
estimated by computing the odds ratios (OR) and 95  % 
confidence intervals (95 % CI) from the Chi-square test 
or Fisher’s exact test. Logistic regression analysis was 
performed to adjust for conventional risk factors includ-
ing age and gender. Two-sided significance level was 0.05. 
The statistical analyses were performed by SPSS 13.0 
(SPSS Inc., Chicago, IL, USA).
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